Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Boston, Massachusetts

Cancer biologic therapy trials in Boston, MA

61 cancer biologic therapy studies are recruiting participants at sites in Boston as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Boston at a glance

  • 61 studies are recruiting at a site in Boston.
  • By phase: Phase 1 (11), Phase 1/2 (11), Phase 2 (16), Phase 2/3 (2), Phase 3 (18), No phase (1), Observational (2). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (36), university, hospital or other (13), government (12).
  • By research area: Lymphoma (19), Breast Cancer (16), Lung Cancer (13), Melanoma (8), Prostate Cancer (3), Pancreatic Cancer (2).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Boston

Basic details from each study's public record (the 30 most recently updated of 61). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05422794 · updated
  2. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Dana-Farber Cancer Institute · Tufts Medical Center
    Registry record
    NCT05564377 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Dana Farber Cancer Institute ( Site 0090) · Massachusetts General Hospital Cancer Center ( Site 0091)
    Registry record
    NCT06966700 · updated
  4. Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Dana-Farber Cancer Institute ( Site 0050)
    Registry record
    NCT06686394 · updated
  5. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Tufts Medical Center
    Registry record
    NCT06058377 · updated
  6. Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT07137416 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Lung cancer studies recruiting in Boston

  1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT06767514 · updated
  2. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Dana Farber Cancer Hospital ( Site 0155) · Massachusetts General Hospital ( Site 0136)
    Registry record
    NCT06623422 · updated
  3. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Beth Israel Deaconess Medical Center · Boston Medical Center · Dana-Farber Cancer Institute
    Registry record
    NCT04267848 · updated
  4. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Tufts Medical Center
    Registry record
    NCT06096844 · updated
  5. A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Johnson & Johnson Enterprise Innovation Inc.
    Study site
    Beth Israel Deaconess Medical Center
    Registry record
    NCT06667908 · updated
  6. Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Strand Therapeutics Inc.
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07751042 · updated
  7. A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

    • Phase 3
    • All ages
    • All sexes
    Sponsor
    Pierre Fabre Medicament
    Study site
    Dana Farber Cancer Institute, Brigham and Women's Hospital (Adults and Pediatrics)
    Registry record
    NCT03394365 · updated
  8. Biology of Young Lung Cancer Study: The YOUNG LUNG Study

    • Observational
    • Ages 15 and older
    • All sexes
    Sponsor
    Dana-Farber Cancer Institute
    Study sites
    Dana-Farber Cancer Institute · Massachusetts General Hospital
    Registry record
    NCT05265429 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Boston

  1. The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)

    • No phase
    • Ages 55 to 69
    • Male participants
    Sponsor
    VA Office of Research and Development
    Study site
    VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
    Registry record
    NCT05926102 · updated
  2. A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Dana Farber Cancer Institute
    Registry record
    NCT07164443 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Melanoma studies recruiting in Boston

  1. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

    • Phase 1/2
    • From 6 months, up to 17 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Call for Information (Investigational Site 0026)
    Registry record
    NCT02332668 · updated
  2. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study sites
    Beth Israel Deaconess Medical Center · Massachusetts General Hospital
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Boston, MA on ClinicalTrials.gov.

Lymphoma studies recruiting in Boston

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT06317662 · updated
  2. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Beth Israel Deaconess Medical Center ( Site 0161) · Dana Farber Cancer Institute ( Site 0111)
    Registry record
    NCT06890884 · updated
  3. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Dana-Farber Cancer Institute · Tufts Medical Center
    Registry record
    NCT04269902 · updated
  4. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05675410 · updated
  5. A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT07015242 · updated
  6. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    Tufts Medical Center
    Registry record
    NCT07188558 · updated
  7. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

    • Phase 1/2
    • From 6 months, up to 25 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Dana-Farber Cancer Institute ( Site 1013)
    Registry record
    NCT06395103 · updated
  8. Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Allogene Therapeutics
    Study sites
    Beth Israel Deaconess Medical Center · Massachusetts General Hospital
    Registry record
    NCT06500273 · updated
  9. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT06124157 · updated
  10. CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    City of Hope Medical Center
    Study site
    DFCI/BWH Brigham and Women's Hospital
    Registry record
    NCT06059391 · updated
  11. A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

    • Phase 1
    • Ages 18 to 75
    • All sexes
    Sponsor
    City of Hope Medical Center
    Study site
    Brigham and Women's Hospital
    Registry record
    NCT07020533 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Boston, MA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Boston

  1. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05372614 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Ask about studies near Boston

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call